Don brings more than 20 years of experience in company building, corporate strategy, and business development across a broad range of therapeutic areas, modalities, and development stages. Over the course of his career, he has executed more than $8.3 billion in transactions across the U.S., Europe, and Asia.
Don has served in senior leadership roles at both public and private biotech companies, including as CEO of Carmine Therapeutics and CBO of EG427, AskBio, and Histogenics. He has also held key leadership positions at Sherlock Biosciences, The Medicines Company, Smith & Nephew, and 3M. In addition to his operating roles, Don brings valuable governance experience, serving on the Boards of Aspect Biosystems, Immvention Therapeutix (as Chairman), and Orthox Ltd. (also as Chairman).
He holds a Ph.D. in Molecular Microbiology and Immunology from the University of Missouri School of Medicine and an MBA from the John M. Olin School of Business at Washington University.
When he’s not closing deals or shaping strategy, Don can most often be found in the pool—or in just about any body of water nearby.